Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial
Source: View publication →
The AcT trial demonstrated that a single intravenous bolus of tenecteplase (0.25 mg/kg) is non-inferior to the standard one-hour infusion of alteplase (0.9 mg/kg) in achieving excellent functional outcomes for patients with acute ischemic stroke.
Key Findings
Study Design
Study Limitations
Clinical Significance
The AcT trial provides definitive, large-scale evidence supporting tenecteplase as a safe and effective replacement for alteplase in acute ischemic stroke. Because tenecteplase is administered as a single 5-second bolus—rather than an initial bolus followed by a 1-hour infusion—it vastly simplifies clinical workflow. This is particularly advantageous for 'drip-and-ship' paradigms, as it eliminates the need for intravenous pumps and avoids delays or infusion interruptions during inter-facility transport for endovascular thrombectomy. These findings have catalyzed a major shift in international stroke guidelines toward tenecteplase as the preferred thrombolytic agent.
Historical Context
For more than 25 years following the landmark 1995 NINDS trial, alteplase was the only FDA-approved medical therapy for acute ischemic stroke. Tenecteplase, a genetically engineered variant of alteplase designed to have greater fibrin specificity and a longer half-life, had long superseded alteplase in the treatment of acute myocardial infarction. In stroke, earlier phase II and III trials (such as EXTEND-IA TNK and NOR-TEST) suggested tenecteplase was at least as effective, potentially yielding higher recanalization rates in large vessel occlusions. However, large, pragmatic, definitive data across all thrombolysis-eligible stroke phenotypes were needed to change widespread practice. The 2022 AcT trial served as that definitive pivot point, enrolling the largest stroke cohort for this comparison to date and firmly establishing non-inferiority.
Guided Discussion
High-yield insights from every perspective
How does the molecular structure and pharmacokinetics of tenecteplase differ from alteplase, and why does this allow for a single-bolus administration in acute ischemic stroke?
Key Response
Tenecteplase is a genetically engineered variant of alteplase with specific amino acid substitutions that increase its half-life, resistance to plasminogen activator inhibitor-1 (PAI-1), and fibrin specificity. This longer half-life allows it to be given as a single intravenous bolus over 5 seconds rather than the one-hour continuous infusion required for alteplase.
From a practical workflow perspective in the emergency department, what are the primary advantages of utilizing tenecteplase over alteplase for a patient who is a candidate for endovascular thrombectomy and needs to be transferred to a comprehensive stroke center?
Key Response
Tenecteplase is administered as a single bolus, which eliminates the need to set up an infusion pump and monitor a continuous infusion during inter-facility transport (the 'drip and ship' model). This significantly streamlines ED workflow, reduces door-to-needle and door-to-in/out times, and simplifies the transport process for large vessel occlusion patients.
The AcT trial utilized a pragmatic, open-label design. How might the open-label nature of this trial influence the downstream management of patients, specifically regarding the decision to proceed with endovascular thrombectomy, and how does this affect the interpretation of the primary outcome?
Key Response
In an open-label trial, treating physicians know which thrombolytic the patient received. This knowledge could introduce performance bias, potentially altering the threshold for proceeding with rescue endovascular thrombectomy or the aggressiveness of post-thrombolytic care. Evaluating the rates of EVT between the two arms is crucial to ensure that differences in downstream management did not disproportionately drive the non-inferiority results.
Given the results of the AcT trial alongside trials like EXTEND-IA TNK, how should stroke systems of care reorganize their thrombolytic protocols, and what are the cost-effectiveness and safety implications of making a system-wide switch from alteplase to tenecteplase?
Key Response
The non-inferiority of tenecteplase, combined with its operational simplicity and lower drug cost, provides a compelling case for a system-wide switch. Attendings must consider not just the clinical non-inferiority, but the training required for nursing staff, updating pharmacy protocols, and the potential reduction in medication errors associated with avoiding complex infusion pump setups in acute, high-stress scenarios.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The AcT trial utilized a registry-linked approach and a pre-specified non-inferiority margin of -5% for the primary outcome. How does this pragmatic registry-linked data collection impact the statistical power and risk of type I error in concluding non-inferiority compared to a traditional RCT?
Key Response
Registry-linked trials are highly pragmatic and cost-effective but can suffer from missing data, loss to follow-up, or misclassification in mRS scoring by non-research clinicians. In a non-inferiority trial, misclassification and 'noise' bias the results toward the null, artificially making the two treatments look more similar and increasing the risk of falsely concluding non-inferiority (Type I error). A rigorous statistical critique must evaluate whether intention-to-treat and per-protocol analyses are concordant to mitigate this bias.
As a peer reviewer, how do you assess the threat of ascertainment bias in the AcT trial given its open-label design, particularly concerning secondary safety outcomes like symptomatic intracranial hemorrhage (sICH)?
Key Response
While the primary outcome (mRS at 90 days) can be partially protected via a PROBE (Prospective Randomized Open, Blinded End-point) design, acute safety outcomes like sICH might be subject to ascertainment bias if investigators look more closely for bleeding or order more imaging in one arm. An editor would flag the need for central, blinded adjudication of neuroimaging to ensure safety outcomes were assessed objectively despite the unblinded drug administration.
Based on the robust non-inferiority findings of the AcT trial and corroborating data, how should current AHA/ASA and ESO clinical practice guidelines be updated regarding the tier of recommendation for tenecteplase (0.25 mg/kg) versus alteplase for all eligible acute ischemic stroke patients?
Key Response
Historically, guidelines recommended tenecteplase primarily for patients with large vessel occlusions prior to thrombectomy (based on EXTEND-IA TNK). The AcT trial provides Class I, Level of Evidence A data supporting that tenecteplase is a reasonable alternative (non-inferior) to alteplase for all thrombolysis-eligible acute ischemic stroke patients. Guideline committees should elevate tenecteplase to a first-line agent on par with, or even preferred over, alteplase due to identical efficacy and superior logistical benefits.
Clinical Landscape
Noteworthy Related Trials
NINDS Trial
Tested
Alteplase 0.9 mg/kg
Population
Patients with acute ischemic stroke treated within 3 hours of symptom onset
Comparator
Placebo
Endpoint
Favorable outcome at 3 months across multiple neurologic scales
NOR-TEST
Tested
Tenecteplase 0.4 mg/kg
Population
Patients with acute ischemic stroke eligible for intravenous thrombolysis
Comparator
Alteplase 0.9 mg/kg
Endpoint
Excellent functional outcome (mRS 0-1) at 3 months
EXTEND-IA TNK
Tested
Tenecteplase 0.25 mg/kg
Population
Ischemic stroke patients with large vessel occlusion scheduled for thrombectomy
Comparator
Alteplase 0.9 mg/kg
Endpoint
Substantial reperfusion at initial angiogram
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis